A database of FDA approved therapeutic peptides and proteins
ID1439 | ThPPIDTh1077 | NameUrofollitropin | Peptide SequenceAlpha chain:APDVQDCP Full view | Length203 | Functional ClassificationIb | DiseaseHormonal | BrandBRAVELLE | CompanyFerring Pharmaceuticals Inc. | Physical AppearanceSterile, lyophilized powder used after reconstitution with sterile 0.9% Sodium Chloride Injection | Route of AdministartionIntramuscular and Subcutaneous administration | CategoryFertility Agents | TargetGlutamate carboxypeptidase 2 |
ID1440 | ThPPIDTh1077 | NameUrofollitropin | Peptide SequenceAlpha chain:APDVQDCP Full view | Length203 | Functional ClassificationIb | DiseaseHormonal | BrandMetrodin | CompanyN.A. | Physical AppearanceSterile, lypholized form contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity | Route of AdministartionIntramuscular injection. | CategoryFertility Agents | TargetGlutamate carboxypeptidase 2 |
ID1441 | ThPPIDTh1077 | NameUrofollitropin | Peptide SequenceAlpha chain:APDVQDCP Full view | Length203 | Functional ClassificationIb | DiseaseHormonal | BrandFertinex | CompanyN.A. | Physical AppearanceSterile, lyophilized form contains an acidic, water soluble glycoprotein biologically standardized for FSH gonadotropin activity | Route of AdministartionSubcutaneous injection. | CategoryFertility Agents | TargetGlutamate carboxypeptidase 2 |
ID1447 | ThPPIDTh1080 | NameChoriogonadotropin Alfa | Peptide SequenceAlpha chain: APDVQDC Full view | Length237 | Functional ClassificationIb | DiseaseHormonal | BrandChoriogonadotropin alfa | CompanyEmd serono inc, Ferring pharmaceuticals inc, App pharmaceuticals llc, Bel mar laboratories inc, Bris | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryFertility Agents and Gonadotropins | TargetIntegrin alpha-L, Low affinity immunoglobulin gamma Fc region receptor III-B, Complement C1r subcomponent, Complement C1q subcomponent subunit A, Complement C1q subcomponent subunit B, Complement C1q subcomponent subunit C, Low affinity immunoglobulin gamma Fc region receptor III-A, High affinity immunoglobulin gamma Fc receptor I, Low affinity immunoglobulin gamma Fc region receptor II-a, Low affinity immunoglobulin gamma Fc region receptor II-b, Low affinity immunoglobulin gamma Fc region receptor II-c |
ID1451 | ThPPIDTh1082 | NameFilgrastim | Peptide SequenceMTPLGPASSLPQSFLLKCLE Full view | Length175 | Functional ClassificationIb | DiseaseImmunological | BrandN.A. | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryImmunosuppressive Agents, Antineutropenic Agents and Hematopoietic Agents | TargetLutropin-choriogonadotropic hormone receptor,Follicle-stimulating hormone receptor |
ID1454 | ThPPIDTh1084 | NameBecaplermin | Peptide SequenceSLGSLTIAEPAMIAECKTRT Full view | Length109 | Functional ClassificationIb | DiseaseCardiac | BrandREGRANEX | CompanyOMJ Pharmaceuticals, Inc. San German, Puerto Rico | Physical AppearanceGel: 0.01 %; clear, colorless to straw-colored gel | Route of AdministartionExternal use only | CategoryAngiogenesis Inducing Agents | TargetT-cell surface glycoprotein CD1a,Major histocompatibility complex class I-related gene protein,Integrin alpha-L,T-lymphocyte activation antigen CD86,Low affinity immunoglobulin gamma Fc region receptor II-b,T-cell surface glycoprotein CD4,Integrin beta-1,Integrin alpha-V,Integrin beta-3 |
ID1456 | ThPPIDTh1086 | NameInterferon Alfa-2B, Recombinant | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandINTRON® A | CompanyMerck | Physical AppearancePowder or solution | Route of AdministartionIntramuscular, Subcutaneous, Intralesional, or Intravenous injection | CategoryImmunosuppressive Agents | TargetGranulocyte colony-stimulating factor receptor,Neutrophil elastase, Coagulation factor X,Coagulation factor XI,Coagulation factor VII,Coagulation factor VIII,Prothrombin,Prolow-density lipoprotein receptor-related protein 1,Vitamin K-dependent gamma-carboxylase, Platelet-derived growth factor receptor beta,Platelet-derived growth factor receptor alpha,Alpha-2-macroglobulin |
ID1460 | ThPPIDTh1087 | NameOxytocin | Peptide SequenceCYIQNCPLG Full view | Length9 | Functional ClassificationIb | DiseaseHormonal | BrandPitocin | CompanyJHP Pharmaceuticals | Physical AppearanceSterile, clear, colorless aqueous solution of synthetic oxytocin | Route of AdministartionIntravenous infusion | CategoryOxytocics, Anti-tocolytic Agents and Labor Induction Agents | TargetInterferon alpha/beta receptor 2,Interferon alpha/beta receptor 1, Globotriaosylceramide |
ID1478 | ThPPIDTh1098 | NameExenatide | Peptide SequenceHGEGTFTSDLSKQMEEEAVR Full view | Length39 | Functional ClassificationIb | DiseaseHormonal/Metabolic | BrandBYETTA | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryHypoglycemic Agents | TargetGlucagon-like peptide 1 receptor |
ID1479 | ThPPIDTh1098 | NameExenatide | Peptide SequenceHGEGTFTSDLSKQMEEEAVR Full view | Length39 | Functional ClassificationIb | DiseaseHormonal/Metabolic | BrandBYDUREON | CompanyAmylin Pharmaceuticals | Physical AppearanceWhite to off-white powder that is available in a dosage strength of 2 mg exenatide per vial or per pen | Route of AdministartionN.A. | CategoryHypoglycemic Agents | TargetGlucagon-like peptide 1 receptor |
ID1480 | ThPPIDTh1099 | NameMecasermin | Peptide SequenceGPETLCGAELVDALQFVCGD Full view | Length70 | Functional ClassificationIb | DiseaseHormonal | BrandN.A. | CompanyN.A. | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryN.A. | TargetInsulin-like growth factor 1 receptor,Insulin-like growth factor-binding protein 3,Insulin receptor,Cation-independent mannose-6-phosphate receptor |
ID1520 | ThPPIDTh1107 | NameInsulin Glulisine | Peptide SequenceA chain: GIVEQCCTSIC Full view | Length51 | Functional ClassificationIb | DiseaseHormonal/Metabolic | BrandAPIDRA | Companysanofi-aventis | Physical AppearanceSterile, aqueous, clear, and colorless solution | Route of AdministartionN.A. | CategoryAntidiabetic Agents | TargetInsulin receptor |
ID1530 | ThPPIDTh1109 | NameNesiritide | Peptide SequenceSPKMVQGSGCFGRKMDRISS Full view | Length32 | Functional ClassificationIb | DiseaseCardiac | BrandNATRECOR | CompanyScios unit of Johnson & Johnson, | Physical AppearanceWhite- to off-white lyophilized powder | Route of AdministartionIntravenous injection | CategoryN.A. | TargetN.A. |
ID1531 | ThPPIDTh1110 | NameThymalfasin | Peptide SequenceSDAAVDTSSEITTKDLKEKK Full view | Length28 | Functional ClassificationIb | DiseaseInfectious/Immunological | BrandZadaxin | CompanySciClone Pharmaceuticals (SCLN) | Physical AppearanceN.A. | Route of AdministartionSubcutaneous injection | CategoryN.A. | TargetN.A. |
ID1532 | ThPPIDTh1111 | NameDefibrotide | Peptide SequenceN.A. Full view | Length0 | Functional ClassificationIb | DiseaseImmunological | BrandNoravid | Companysanofi-aventis | Physical AppearanceN.A. | Route of AdministartionN.A. | CategoryAntithrombins | TargetAdenosine receptor A1,Adenosine receptor A2a,Adenosine receptor A2b |
ID1535 | ThPPIDTh1114 | NamePreotact | Peptide SequenceParathyroid hormone: Full view | Length84 | Functional ClassificationIb | DiseaseOsteological | BrandPreotact | CompanyNycomed | Physical AppearanceN.A. | Route of AdministartionSubcutaneous injection | CategoryN.A. | TargetParathyroid hormone/parathyroid hormone-related peptide receptor,Parathyroid hormone 2 receptor |
ID1556 | ThPPIDTh1120 | NameTeriparatide | Peptide SequenceParathyroid hormone Full view | Length34 | Functional ClassificationIb | DiseaseOsteological | BrandForteo | CompanyEli Lilly and Company | Physical AppearanceSterile, colorless, clear, isotonic solution | Route of AdministartionSubcutaneous injection | CategoryBone Density Conservation Agents | TargetParathyroid hormone/parathyroid hormone-related peptide receptor |
ID1576 | ThPPIDTh1124 | NameLiraglutide | Peptide SequenceHAEGTFTSDVSSYLEGQAAK Full view | Length33 | Functional ClassificationIb | DiseaseHormonal | BrandSaxenda | CompanyNovo Nordisk | Physical AppearanceClear, colorless solution | Route of AdministartionSubcutaneous injection | CategoryN.A. | TargetGlucagon-like peptide 1 receptor |
ID1577 | ThPPIDTh1124 | NameLiraglutide | Peptide SequenceHAEGTFTSDVSSYLEGQAAK Full view | Length33 | Functional ClassificationIb | DiseaseHormonal | BrandVictoza | CompanyNovo Nordisk | Physical AppearanceClear, colorless solution. | Route of AdministartionSubcutaneous injection | CategoryN.A. | TargetGlucagon-like peptide 1 receptor |
ID1603 | ThPPIDTh1129 | NameTesamorelin | Peptide SequenceYADAIFTNSYRKVLGQLSAR Full view | Length44 | Functional ClassificationIb | DiseaseHormonal | BrandEgrifta | CompanyTheratechnologies | Physical AppearanceSterile, white to off-white, preservative-free lyophilized powder | Route of AdministartionSubcutaneous injection | CategoryN.A. | TargetGrowth hormone-releasing hormone receptor |
ID1615 | ThPPIDTh1133 | NameAflibercept | Peptide SequenceSDTGRPFVEMYSEIPEIIHM Full view | Length431 | Functional ClassificationIb | DiseaseCancer | BrandEylea | CompanyRegeneron Pharmaceuticals | Physical AppearanceSterile, clear, and colorless to pale yellow solution. | Route of AdministartionIntravitreal injection | CategoryAntineoplastic Agents and Ophthalmics | TargetVascular endothelial growth factor A,Placenta growth factor,Vascular endothelial growth factor B |
ID1616 | ThPPIDTh1133 | NameAflibercept | Peptide SequenceSDTGRPFVEMYSEIPEIIHM Full view | Length431 | Functional ClassificationIb | DiseaseCancer | BrandZaltrap | CompanySanofi and Regeneron Pharmaceuticals, Inc. | Physical AppearanceSterile, clear, colorless to pale yellow, non-pyrogenic, preservative-free, solution. | Route of AdministartionIntravenous infusion | CategoryAntineoplastic Agents and Ophthalmics | TargetVascular endothelial growth factor A,Placenta growth factor,Vascular endothelial growth factor B |
ID1635 | ThPPIDTh1141 | NameEpoetin Zeta | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseCancer | BrandRetacrit | CompanyNorbitec | Physical Appearancesolution for injection | Route of AdministartionN.A. | CategoryN.A. | TargetErythropoietin receptor |
ID1638 | ThPPIDTh1144 | NameFollitropin Alpha | Peptide SequenceN.A. Full view | Length0 | Functional ClassificationIb | DiseaseAdjunct therapy/ Hormonal | BrandGonal-F | CompanySerono Laboratories | Physical AppearanceSterile, lyophilized powder. | Route of AdministartionSubcutaneous injection | CategoryN.A. | TargetN.A. |
ID1639 | ThPPIDTh1144 | NameFollitropin Alpha | Peptide SequenceN.A. Full view | Length0 | Functional ClassificationIb | DiseaseAdjunct therapy/ Hormonal | BrandGonal-f RFF | CompanyEMD SERONO | Physical AppearanceSterile, lyophilized powde | Route of AdministartionSubcutaneous injection | CategoryN.A. | TargetN.A. |
ID1640 | ThPPIDTh1145 | NameRomiplostim | Peptide SequenceThrombopoietin recep Full view | Length269 | Functional ClassificationIb | DiseaseImmunologcal | BrandNplate | CompanyAmgen | Physical AppearanceSterile, preservative-free, lyophilized, solid white powder | Route of AdministartionSubcutaneous injection | CategoryColony-Stimulating Factors and Thrombopoietic Agents | TargetN.A. |
ID1641 | ThPPIDTh1146 | NameLucinactant | Peptide SequenceKLLLLKLLLLKLLLLKLLLL Full view | Length21 | Functional ClassificationIb | DiseaseGenetic | BrandSurfaxin | CompanyDiscovery Laboratories, Inc. | Physical AppearanceSuspension | Route of AdministartionIntratracheal administration | CategoryPulmonary surfactants | TargetN.A. |
ID1655 | ThPPIDTh1151 | NameSomatotropin Recombinant | Peptide SequenceFPTIPLSRLFDNAMLRAHRL Full view | Length192 | Functional ClassificationIb | DiseaseHormonal/Metabolic | BrandNutropinAQ | CompanyGenentech Inc. | Physical AppearanceSterile, white lyophilized powder intended for subcutaneous administration after reconstitution with Bacteriostatic Water | Route of AdministartionSubcutaneous administration | CategoryHormone Replacement Agents | TargetGrowth hormone receptor, Prolactin receptor |
ID1656 | ThPPIDTh1151 | NameSomatotropin Recombinant | Peptide SequenceFPTIPLSRLFDNAMLRAHRL Full view | Length192 | Functional ClassificationIb | DiseaseHormonal/Metabolic | BrandBioTropin | CompanyBio-Technology General (Israel) Ltd. | Physical AppearanceSterile, white, lyophilized powder | Route of AdministartionSubcutaneous administration | CategoryHormone Replacement Agents | TargetGrowth hormone receptor, Prolactin receptor |
ID1657 | ThPPIDTh1151 | NameSomatotropin Recombinant | Peptide SequenceFPTIPLSRLFDNAMLRAHRL Full view | Length192 | Functional ClassificationIb | DiseaseHormonal/Metabolic | BrandProtropin | CompanyGenentech Inc. | Physical AppearanceSterile, white, lyophilized powder | Route of AdministartionIntramuscular or subcutaneous administration | CategoryHormone Replacement Agents | TargetGrowth hormone receptor, Prolactin receptor |
ID1659 | ThPPIDTh1152 | NameDrotrecogin alfa | Peptide SequenceHeavy Chain: LIDGKMT Full view | Length402 | Functional ClassificationIb | DiseaseInfectious | BrandXigris | CompanyEli Lilly and Company | Physical AppearanceSterile, lyophilized, white to off-white powder | Route of AdministartionIntravenous Infusion | CategoryAntisepsis | TargetCoagulation factor VIII, V, Plasminogen activator inhibitor 1, Thrombomodulin, Vitamin K-dependent protein S, Ceruloplasmin, Prothrombin, Platelet factor 4, Plasma serine protease inhibitor, Serpin B6, Vitamin K-dependent gamma-carboxylase, Endothelial protein C receptor |
ID1663 | ThPPIDTh1155 | NameUrokinase | Peptide SequenceKPSSPPEELKFQCGQKTLRP Full view | Length276 | Functional ClassificationIb | DiseaseHaemetological | BrandKinlytic | CompanyN.A. | Physical AppearanceSterile lyophilized white powder | Route of AdministartionIntravenous infusion | CategoryN.A. | TargetPlasminogen,Urokinase plasminogen activator surface receptor, Urokinase-type plasminogen activator, Tissue-type plasminogen activator, Plasminogen activator inhibitor 1, 2, Plasma serine protease inhibitor, Low-density lipoprotein receptor-related protein 2, Suppressor of tumorigenicity 14 protein, Nidogen-1 |
ID1674 | ThPPIDTh1161 | NameAlbiglutide | Peptide SequenceHGEGTFTSDVSSYLEGQAAK Full view | Length645 | Functional ClassificationIb | DiseaseHormonal disorders | BrandEperzan | CompanyGlaxosmithkline Inc | Physical AppearancePowder for Solution | Route of AdministartionSubcutaneous | CategoryDrugs used in diabetes; alimentary tract and metabolism; blood glucose lowering drugs, excl. insulins. | TargetGlucagon-like peptide 1 receptor |
ID1676 | ThPPIDTh1161 | NameAlbiglutide | Peptide SequenceHGEGTFTSDVSSYLEGQAAK Full view | Length645 | Functional ClassificationIb | DiseaseHormonal disorders | BrandTanzeum | CompanyGlaxo Smith Kline Llc | Physical AppearanceInjection, Powder, Lyophilized, for Solution | Route of AdministartionSubcutaneous | CategoryDrugs used in diabetes; alimentary tract and metabolism; blood glucose lowering drugs, excl. insulins. | TargetGlucagon-like peptide 1 receptor |
ID1682 | ThPPIDTh1163 | NameAncestim | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseCancer | BrandStemgen | CompanyBiovitrum Ab (publ) | Physical AppearanceNA | Route of AdministartionSubcutaneous | CategoryNA | TargetNA |
ID1726 | ThPPIDTh1175 | NameDesirudin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandIprivask | CompanyValeant Pharmaceuticals North America LLC | Physical AppearanceNA | Route of AdministartionSubcutaneous | CategoryNA | TargetNA |
ID1727 | ThPPIDTh1175 | NameDesirudin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandIprivask | CompanyMarathon Pharmaceuticals, LLC | Physical AppearanceNA | Route of AdministartionNA | CategoryNA | TargetNA |
ID1729 | ThPPIDTh1176 | NameDulaglutide | Peptide SequenceHGEGTFTSDVSSYLEEQAAK Full view | Length275 | Functional ClassificationIb | DiseaseMetabolic Disorders | BrandTrulicity | CompanyEli Lilly and Company | Physical AppearanceSolution, Injection | Route of AdministartionSubcutaneous | CategoryHypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins | TargetGlucagon-like peptide 1 receptor |
ID1730 | ThPPIDTh1176 | NameDulaglutide | Peptide SequenceHGEGTFTSDVSSYLEEQAAK Full view | Length275 | Functional ClassificationIb | DiseaseMetabolic Disorders | BrandTrulicity | CompanyEli Lilly Canada Inc | Physical AppearanceSolution | Route of AdministartionSubcutaneous | CategoryHypoglycemic Agents; Drugs Used in Diabetes; Alimentary Tract and Metabolism; Blood Glucose Lowering Drugs, Excl. Insulins | TargetGlucagon-like peptide 1 receptor |
ID1756 | ThPPIDTh1182 | NameGastric intrinsic factor | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHormonal Disorders | BrandHematogen | CompanyNnodum Pharmaceuticals | Physical AppearanceNA | Route of AdministartionNA | CategoryNA | TargetNA |
ID1765 | ThPPIDTh1184 | NameHuman calcitonin | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHormonal Disorders | BrandNA | CompanyNA | Physical AppearanceNA | Route of AdministartionNA | CategoryNA | TargetNA |
ID1780 | ThPPIDTh1188 | NameHyaluronidase (Human Recombinant) | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseAdjunct therapy | BrandNA | CompanyNA | Physical AppearanceNA | Route of AdministartionNA | CategoryNA | TargetHyaluronan; Transforming growth factor beta-1 |
ID1782 | ThPPIDTh1189 | NameIdarucizumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandPraxbind | CompanyBoehringer Ingelheim Pharmaceuticals, Inc. | Physical AppearanceInjection | Route of AdministartionIntravenous | CategoryAnticoagulant | TargetNA |
ID1817 | ThPPIDTh1208 | NameMetreleptin | Peptide SequenceMVPIQKVQDDTKTLIKTIVT Full view | Length147 | Functional ClassificationIb | DiseaseAdjunct therapy | BrandMyalept | CompanyAmylin Pharmaceuticals, LLC | Physical AppearanceLyophilized Powder for Solution | Route of AdministartionSubcutaneous | Category | TargetLeptin receptor |
ID1818 | ThPPIDTh1209 | NameMethoxy polyethylene glycol-epoetin beta | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandMircera | CompanyGenentech, Inc. | Physical AppearanceSolution for Injection | Route of AdministartionIntravenous | CategoryNA | Target |
ID1819 | ThPPIDTh1210 | NameMepolizumab | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseRespiratory Disorder | BrandNucala | CompanyGlaxosmithkline Inc | Physical AppearanceLyophilized Powder | Route of AdministartionSubcutaneous | CategoryAntineoplastic and Immunomodulating Agents, Immunosuppressive Agents, Interleukin Inhibitors | TargetInterleukin-5 |
ID1824 | ThPPIDTh1215 | NameThyroglobulin | Peptide SequenceMALVLEIFTLLASICWVSAN Full view | Length0 | Functional ClassificationIb | DiseaseHormonal disorders | BrandNA | CompanyNA | Physical AppearanceNA | Route of AdministartionNA | CategoryNA | TargetNA |
ID1836 | ThPPIDTh1225 | NameCoagulation factor X human | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandCoagadex | CompanyNA | Physical Appearancepowder and solvent used to make a solution | Route of AdministartionIntravenous | CategoryBlood Coagulation Factors | TargetNA |
ID1838 | ThPPIDTh1227 | NameEfmoroctocog alfa | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandELOCTA | CompanyNA | Physical AppearancePowder and solvent for solution for injection | Route of AdministartionIntravenous | CategoryAntihemophilic Factor | TargetNA |
ID1839 | ThPPIDTh1228 | NameFactor IX Complex (Human) | Peptide SequenceNA Full view | Length0 | Functional ClassificationIb | DiseaseHematological Disorders | BrandAlphaNine SD or Mononine | Company | Physical AppearancePowder and solvent for solution for injection | Route of AdministartionIntravenous | CategoryAntihemophilic agent | TargetNA |